CLRB

Insider Trades

Name	Value	Action	Price	Current Price
Caruso James VDirector, Officer: Chief Executive Officer $75k26k shares BuyMay 7, 2026 $2.88 --
Longcor JarrodChief Operating Officer $75k26k shares BuyMay 7, 2026 $2.88 --
Caruso James VDirector, Officer: Chief Executive Officer $25k8.7k shares BuyMay 7, 2026 $2.88 --
Longcor JarrodChief Operating Officer $25k8.7k shares BuyMay 7, 2026 $2.88 --
Neis JohnDirector $732198 shares SellDec 12, 2025 $3.70 --
Caruso James VDirector, Officer: Chief Executive Officer $53k10k shares BuyJul 2, 2025 $5.25 --

News

globenewswire.comCellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meetingglobenewswire.comJun 1

seekingalpha.comCellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 14

globenewswire.comCellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updatesglobenewswire.comMay 14

Trade CLRB

About Cellectar Biosciences, Inc.

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.

CEO: James V. Caruso
IPO Date: Nov 10, 2005

Market Data

Volume: 292.7K

Valuation

Market Cap: $8.0M

Financials

Financial statement snapshot is not available yet.

Events

EarningsAug 13

EPS est. -0.47